Evoke Pharma, Inc. EVOK
At closeDec 17, 2025, 4:00 PM EST
After hours · Dec 17, 4:00 PM ET
52-week range unavailable
- YTD
- +148.87%
- 1 year
- +139.65%
- Market cap
- 7.37M
- Revenue (ttm)
- 8.62M
- Profit margin
- -71.33%
- Shares out
- 1.49M
- Forward P/E
- 10.33
- YTD return
- +148.87%
- 1-year return
- +139.65%
- Volume
- 47.10K
- Open
- 11.00
- Previous close
- 11.00
- Day's range
- 11.00 – 11.00
- Beta
- 0.35
- Price target
- 18.00 (+63.6%)
Key statistics
- Enterprise value
- 1.20M
- PEG ratio
- 0.00
- Price / sales
- 0.86
- Price / book
- 1.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 69.80%
- Free cash flow
- -1.49M
- Total cash
- 11.34M
- Total debt
- 5.00M
- Return on equity
- -349.91%
- Short % of float
- 1.70%
- 50-day average
- 4.97
- 200-day average
- 5.60
Analyst view
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.63.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -0.94 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.93 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -2.04 | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | -7.08 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -6.12 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -6.72 | — | — |
About Evoke Pharma, Inc.
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- evokepharma.com
News
Evoke revenue falls 7% to £406m as shop closures and customer-friendly results weigh 
Evoke H1 Earnings Call Highlights 
Evoke shares jump 16% as William Hill owner agrees £243m takeover by Bally's Intralot 
Evoke Agrees to $326 Million Takeover Bid From Bally's Intralot 
William Hill UK owner Evoke agrees $326 million takeover by Bally's Intralot 
William Hill owner Evoke in talks with Ball's Intralot about potential takeover 
William Hill UK owner Evoke confirms $304 million takeover bid from Bally's Intralot 
William Hill owner Evoke reports strongest quarter of the year, sale process ongoing 
Deutsche Bank downgrades Evoke and Rank as gaming outlook resets 
Evoke Pharma and QOL Medical Announce Expiration of Tender Offer
Your note
Sign in to keep a note on EVOK — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 4.75% | 70,546 | 349.91K | Sep 29, 2024 |
| Bleichroeder LP | 4.63% | 68,750 | 341.00K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.79% | 56,249 | 279.00K | Sep 29, 2024 |
| Corsair Capital Management, L.P. | 0.79% | 11,667 | 57.87K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.05% | 816 | 4.05K | Sep 29, 2024 |
| Blackrock Inc. | 0.01% | 122 | 605 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.17% | 2,487 | 12.34K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.16% | 2,404 | 11.92K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 1,496 | 7.42K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 373 | 1.85K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 41 | 203 | Oct 30, 2024 |